- Home
- RCG vs BLRX Comparison
RCG vs BLRX Comparison
Compare RCG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCG
- BLRX
- Stock Information
- Founded
- RCG 1994
- BLRX 2003
- Country
- RCG United States
- BLRX Israel
- Employees
- RCG N/A
- BLRX N/A
- Industry
- RCG Investment Managers
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RCG Finance
- BLRX Health Care
- Exchange
- RCG Nasdaq
- BLRX Nasdaq
- Market Cap
- RCG N/A
- BLRX 12.2M
- IPO Year
- RCG N/A
- BLRX 2011
- Fundamental
- Price
- RCG $2.55
- BLRX $2.92
- Analyst Decision
- RCG
- BLRX Strong Buy
- Analyst Count
- RCG 0
- BLRX 2
- Target Price
- RCG N/A
- BLRX $53.00
- AVG Volume (30 Days)
- RCG 5.9K
- BLRX 25.8K
- Earning Date
- RCG 01-01-0001
- BLRX 03-31-2025
- Dividend Yield
- RCG 0.98%
- BLRX N/A
- EPS Growth
- RCG N/A
- BLRX N/A
- EPS
- RCG N/A
- BLRX N/A
- Revenue
- RCG N/A
- BLRX $28,940,000.00
- Revenue This Year
- RCG N/A
- BLRX N/A
- Revenue Next Year
- RCG N/A
- BLRX N/A
- P/E Ratio
- RCG N/A
- BLRX N/A
- Revenue Growth
- RCG N/A
- BLRX 502.92
- 52 Week Low
- RCG $1.52
- BLRX $2.85
- 52 Week High
- RCG $1.90
- BLRX $37.20
- Technical
- Relative Strength Index (RSI)
- RCG 46.60
- BLRX 34.77
- Support Level
- RCG $2.46
- BLRX $3.01
- Resistance Level
- RCG $2.69
- BLRX $3.61
- Average True Range (ATR)
- RCG 0.13
- BLRX 0.21
- MACD
- RCG -0.01
- BLRX 0.02
- Stochastic Oscillator
- RCG 59.18
- BLRX 9.21
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.